These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 6151111)

  • 1. Effect of a zinc phosphate suspension of a long-acting somatostatin analog on postprandial plasma glucose, triglyceride and glucagon concentrations in alloxan diabetic dogs.
    Martin C; Wallum B; Krom B; Hall L; Gerich J
    Life Sci; 1984 Dec; 35(26):2627-33. PubMed ID: 6151111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superactive somatostatin analog decreases plasma glucose and glucagon levels in diabetic rats.
    Karashima T; Schally AV
    Peptides; 1988; 9(3):561-5. PubMed ID: 2901737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus.
    Dimitriadis G; Tessari P; Gerich J
    Metabolism; 1983 Oct; 32(10):987-92. PubMed ID: 6136893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical reduction in pancreatic glucagon with normalization of somatostatin and decrease in insulin in normoglycemic alloxan-diabetic dogs: a putative mechanism of glucagon irresponsiveness to hypoglycemia.
    Rastogi KS; Lickley L; Jokay M; Efendic S; Vranic M
    Endocrinology; 1990 Feb; 126(2):1096-104. PubMed ID: 1967577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients.
    Tsai AC; Vinik AI; Lasichak A; Lo GS
    Am J Clin Nutr; 1987 Mar; 45(3):596-601. PubMed ID: 2881482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a long acting glucagon selective somatostatin analogue on plasma glucose, insulin and glucagon levels in the anaesthetized rat during arginine infusion.
    Lien E; Sarantakis D
    Diabetologia; 1979 Jul; 17(1):59-64. PubMed ID: 467854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L-363,586) in insulin-dependent diabetes mellitus.
    Gottesman I; Tobert J; Vandlen R; Gerich J
    Life Sci; 1986 Jun; 38(24):2211-9. PubMed ID: 2872569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of streptozotocin-diabetic dogs with a long-acting somatostatin analog.
    Lien EL; Greenwood J; Sarantakis D
    Diabetes; 1979 May; 28(5):491-5. PubMed ID: 437379
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration.
    Starke A; Imamura T; Unger RH
    J Clin Invest; 1987 Jan; 79(1):20-4. PubMed ID: 2878938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon suppression improves glucoregulation in moderate but not chronic severe diabetes.
    Lickley HL; Kemmer FW; Doi K; Vranic M
    Am J Physiol; 1983 Oct; 245(4):E424-9. PubMed ID: 6137957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs.
    Sakurai H; Dobbs R; Unger RH
    J Clin Invest; 1974 Dec; 54(6):1395-402. PubMed ID: 4436439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin analogs as glucagon suppressants in diabetes.
    Schusdziarra V; Rivier J; Dobbs R; Brown M; Vale W; Unger R
    Horm Metab Res; 1978 Nov; 10(6):563-5. PubMed ID: 744579
    [No Abstract]   [Full Text] [Related]  

  • 13. [des-Ala1, Gly2]-His4,5D-Trp8-somatostatin: a glucagon-specific and long-acting somatostatin analog.
    Sarantakis D; Teichman J; Fenichel R; Lien E
    FEBS Lett; 1978 Aug; 92(2):153-5. PubMed ID: 700091
    [No Abstract]   [Full Text] [Related]  

  • 14. A super active cyclic hexapeptide analog of somatostatin.
    Veber DF; Saperstein R; Nutt RF; Freidinger RM; Brady SF; Curley P; Perlow DS; Paleveda WJ; Colton CD; Zacchei AG
    Life Sci; 1984 Apr; 34(14):1371-8. PubMed ID: 6143233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
    Spinas GA; Bock A; Keller U
    Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus.
    Gerich JE; Lorenzi M; Karam JH; Schneider V; Forsham PH
    JAMA; 1975 Oct; 234(2):159-5. PubMed ID: 1242153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of glucagon in mediating epinephrine-induced hyperglycemia in alloxan-diabetic dogs.
    Perez G; Kemmer FW; Lickley HL; Vranic M
    Am J Physiol; 1981 Oct; 241(4):E328-35. PubMed ID: 7032319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
    Williams G; Füessl HS; Burrin JM; Chilvers E; Bloom SR
    Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profiles in patients with insulin-dependent diabetes mellitus.
    Dimitriadis G; Gerich J
    Horm Metab Res; 1985 Oct; 17(10):510-1. PubMed ID: 2866155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of metabolic control determines role of epinephrine-glucagon interaction in glucoregulation in diabetes.
    Kemmer FW; Lickley HL; Gray DE; Perez G; Vranic M
    Am J Physiol; 1982 Jun; 242(6):E428-36. PubMed ID: 6124126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.